Covid-19 Research Funding Opportunities Exist!
Eager to help stop COVID-19 by doing great research? Here’s a running list of COVID-19 funding opportunities:
Get up to $3 Million to Build Treatments
Get as much as $3 million from the ITM’s parent organization, the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (NCATS), to build on your work testing medicines related to the virus and/or repurposing existing treatments for other diseases to help fight COVID-19.
Get up to $750K for Your Translational Research
Calling all translational science experts! Get as much as $750,000 for your COVID-19 research with these NCATS opportunities. Secure that funding for your work harnessing informatics to diagnose people or your research using resources from the Clinical and Translational Science Award (CTSA) hubs like the ITM to transform lab findings into treatments and vaccines.
Pivot Your Current Research
Is your ongoing research relevant to COVID-19 in any way? Pivot your project to tackle COVID-19 directly with this NIH National Institute of General Medical Sciences (NIGMS) opportunity.
Revamp Your Research on Heart, Lung, and Blood Diseases
Your research on heart, lung, and blood diseases could help answer the many questions surrounding COVID-19. Refocus your work to address the virus with this NIH National Heart, Lung, and Blood Institute (NHLBI) opportunity.
Adapt Your Research on Drug Use
COVID-19 impacts certain populations differently, like those with substance use disorders, HIV, or people who are in prison. Revise your research to find out how the virus is affecting those people and how to help them with this NIH National Institute on Drug Abuse (NIDA) opportunity.
Refocus Your Infectious Disease Research
Channel your infectious disease research to learn more about COVID-19 spreads, how it works, how to diagnose it, and to build treatments and vaccines with this NIH National Institute of Allergy and Infectious Diseases (NIAID) opportunity.
Adjust Your DNA Research
Reframe your genetic research to learn more about how COVID-19 works, spreads, and how to find and treat it with this NIH National Human Genome Research Institute (NHGRI) opportunity.
Secure $10K for Your Innovative Idea
Get up to $10,000 in funding for your innovative COVID-19 project from the University of Chicago’s Center for Healthcare Delivery Science and Innovation (HDSI). HDSI is looking for great ideas tackling everything from screening systems to designing supplies to mental health care. You can submit your ideas on a rolling basis.
About the Institute for Translational Medicine (ITM)
The Institute for Translational Medicine (ITM) helps you live your best life by making research breakthroughs happen and getting those discoveries into the real world to improve your health as soon as possible.
The ITM is a partnership between the University of Chicago and Rush in collaboration with Advocate Health Care, the Illinois Institute of Technology (Illinois Tech), Loyola University Chicago, and NorthShore University HealthSystem that’s fueled by about $35 million in grants from the National Center for Advancing Translational Sciences at the National Institutes of Health through its Clinical and Translational Science Awards (CTSA) Program.
We’re part of a network of more than 55 CTSA Program-supported hubs across the country working to slash the time it takes to develop and share new treatments and health approaches. We work with you and for you to make participating in health research easy, so that together we improve health care for all.
Join the movement and learn more about how we help researchers, physicians, community members, industry, government organizations, and others. Visit us at chicagoitm.org and connect with us on Facebook, Twitter, Instagram, YouTube, and LinkedIn @ChicagoITM.
This project is supported by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) through Grant Numbers 5UL1TR002389-02, 5KL2TR002387-02, and 5TL1TR002388-02that fund the Institute for Translational Medicine (ITM). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.